Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250351 | 0.91 | RAB9A (0.84) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL15362323 | 0.91 | ALDH1A1 (1.00) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL24072673 | 0.91 | RAB9A (0.98) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL30292744 | 0.88 | RAB9A (0.67) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL24072134 | 0.88 | ALDH1A1 (1.00) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL24071842 | 0.88 | RAB9A (0.84) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL612760 | 0.88 | CYP2C19 (1.00) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL7534615 | 0.87 | ALDH1A1 (1.00) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL24072215 | 0.86 | RAB9A (0.85) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL24072211 | 0.86 | RAB9A (0.82) | RAB9AALDH1A1SMN1; SMN2CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| EP-4157263-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | The Regents Of The University Of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | RAB9A 839/4885ALDH1A1 2339/4885SMN1; SMN2 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.